Please login to the form below

Not currently logged in
Email:
Password:

lung cancer

This page shows the latest lung cancer news and features for those working in and with pharma, biotech and healthcare.

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

in previously-untreated patients with extensive-stage SCLC, said to be the most aggressive for of lung cancer. ... SCLC is less common than non-small cell lung cancer (NSCLC) but tends to be more aggressive, growing more quickly and spreading to other

Latest news

  • Boehringer bags FDA OK for Ofev in rare lung disease ILD Boehringer bags FDA OK for Ofev in rare lung disease ILD

    FGF receptors – achieved a 44% reduction in the rate of decline of lung function over 52 weeks compared to placebo. ... Ofev’s active ingredient nintedanib is also sold as Vargatef for some types of non-small cell lung cancer (NSCLC).

  • Amgen reveals more data on KRAS drug Amgen reveals more data on KRAS drug

    G12C-positive non-small cell lung cancer (NSCLC). ... reported at the World Conference on Lung Cancer over the weekend.

  • Roche scores EU approval twice for Tecentriq in lung cancer Roche scores EU approval twice for Tecentriq in lung cancer

    immunotherapy Tecentriq, in both extensive-stage small cell lung cancer (ES-CLC) and non-squamous non-small cell lung cancer (NSCLC). ... competition from other checkpoint inhibitors, particularly MSD’s Keytruda (pembrolizumab), which has the largest

  • Novartis’ lung cancer drug wins FDA Breakthrough Therapy Designation Novartis’ lung cancer drug wins FDA Breakthrough Therapy Designation

    Provides hope for new treatment of rare cancer. Novartis’ investigational therapy capmatinib for patients with MET-mutated advanced non-small cell lung cancer (NSCLC) has received Breakthrough Therapy Designation (BTD) from ... However, rival Merck

  • MSD’s Keytruda catches up in kidney cancer MSD’s Keytruda catches up in kidney cancer

    The blockbuster drug is approved in a variety of cancer types, with its most notable lead being the lung cancer market. ... has the upper hand, with its approval in the lucrative first-line lung cancer indication helping with sales momentum.

More from news
Approximately 100 fully matching, plus 757 partially matching documents found.

Latest Intelligence

  • AI is transforming pharma R&D – now it can transform pharma marketing AI is transforming pharma R&D – now it can transform pharma marketing

    In May 2019, Google reported that its AI could detect early signs of lung cancer in CT scans, in some cases identifying cancers missed by trained oncologists. ... A successful colonoscopy may prevent a cancer being missed, so Ava might help save lives!

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    Back in 2016, Chinese scientists led by oncologist Lu You at Sichuan University in Chengdu, injected CRISPR-modified cells into a patient with a form of lung cancer at the West ... hope was that - without the brake of PD-1 – the edited cells would

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... April. Naturally Merck &Co isn’t confining itself to dominance in lung cancer.

  • China’s clinical trial shake-up China’s clinical trial shake-up

    For example, around 40% of new lung cancer diagnoses worldwide are in China. ... Once seen as a manufacturer of generics rather than a developer of innovative drugs, China is now involved in half of all enrolling cancer trials of CAR-T cell therapies.

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    of this include recent deals on CAR-T therapies, plus a new expansion in the use of Keytruda in lung cancer, announced late last year. ... Value assessment. More and faster NICE appraisals for new medicines including speeding up the appraisal of

More from intelligence
Approximately 1 fully matching, plus 49 partially matching documents found.

Latest appointments

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Iris Pauporté joins OSE Immunotherapeutics Iris Pauporté joins OSE Immunotherapeutics

    Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice

  • Merck appoints ex-Pfizer exec as global head of oncology Merck appoints ex-Pfizer exec as global head of oncology

    lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer.

  • Merck appoints new senior vice president Merck appoints new senior vice president

    Radvanyi will focus on leading the discovery of oncology therapies that leverage the natural ability of the body's immune system to fight cancer, as well as identifying biomarkers with the ... indications including lung, cervical and breast cancer.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Red Health

Red Health was formed in 2007 to bring something fresh to the healthcare PR world. Our approach was simple –...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics